Session Type: Abstract Submissions (ACR)
To analyze the clinical and biological characteristics associated with presence of antibodies to Infliximab, in rheumatoid arthritis (RA) and spondyloarthritis patients (SpA).
Sera from RA (n=22) or SpA (n=23) patients receiving Infliximab have been analyzed with a commercial multiplex enzyme-linked immunosorbent assay kit (LISA-Tracker Infliximab BMD®). Antibodies toward Infliximab (ATI) and Infliximab trough concentrations were measured in their serum. Result was considered positive if ATI concentrations were >10ng/mL. Clinical and biological data were retrospectively collected from the patient’s medical file.
Infliximab was given in association with methotrexate in 31 patients (69%). The time between two consecutive Infliximab adminstration was higher than 8 weeks in Fifteen patients (33%). Fifteen patients were in remission at time of analysis. Time between two Infliximab administration was significantly longer in patients who had obtained remission(9.27 weeks) compared to other patients(6.83 weeks; Mann-Whitney Test, p=0.0005).
Seven patients(15%) were ATI+. Time since beginning of Infliximab was not different between ATI+ and ATI- patients.
Posology of Infliximab at time of analysis was not different between ATI+ (4.29mg/kg) and ATI- patients(4.13mg/kg; Mann-Whitney Test, p=0.74).
Longer time between infliximab infusions was associated with presence of ATI(ATI +: 9.57 weeks; ATI -: 7.29 weeks; Mann-Whitney Test p=0.02). As expected, Infliximab concentration was significantly lower in ATI+ patients(0.18μg/mL) compared to ATI- patients(2.1μg/mL; Mann-Whitney Test, p=0.0005). There was a significant inverse correlation between ATI titer and Infliximab concentration in the serum(Spearman test, p=0.0001). In contrast, no association was found between the posology of Methotrexate and presence of ATI.
Immunogenicity against Infliximab was associated to a longer interval between infusions. This result could impact on treatment strategy for patients in clinical remission since decreasing the frequency of Infliximab administration may favor the development of ATI.
M. L. Potier,
« Back to 2012 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/immunogenicity-of-infliximab-is-related-to-reduction-of-frequency-of-infliximab-administration-in-rheumatoid-arthritis-and-spondyloarthritis-patients/